预约演示
更新于：2025-02-20
Pentoxifylline
己酮可可碱
更新于：2025-02-20
概要
基本信息
药物类型 小分子化药 |
别名 Oxpentifylline、Pentoxfylline、Pentoxifylline (JAN/USP/INN) + [44] |
作用机制 PDE inhibitors、TNF-α抑制剂(肿瘤坏死因子α抑制剂) |
非在研适应症- |
最高研发阶段批准上市 |
首次获批日期 美国 (1984-08-30), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C13H18N4O3 |
InChIKeyBYPFEZZEUUWMEJ-UHFFFAOYSA-N |
CAS号6493-05-6 |
关联
304
项与 己酮可可碱 相关的临床试验NCT06494111
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
NCT06823362
Bioequivalence Study of Pentoxifylline 400 Mg in Sustained Release Tablets in Sustained Release Tablets in Healthy Subjects Under Fasting and Fed Conditions
IRCT20221108056446N11
Effect of combination of surgery, Low-Level Laser, vitamin E and Pentoxifylline on treatment of medication Related Osteonecrosis of Jaw
100 项与 己酮可可碱 相关的临床结果
登录后查看更多信息
100 项与 己酮可可碱 相关的转化医学
登录后查看更多信息
100 项与 己酮可可碱 相关的专利（医药）
登录后查看更多信息
7,366
项与 己酮可可碱 相关的文献（医药）2025-03-01LARYNGOSCOPE
Presentation and Optimal Management of Anterior and Central Skull Base Osteoradionecrosis: Systematic Review and Meta‐Analysis
Review
作者: Shah, Sunny R. ; Tang, Dennis ; Sindwani, Raj ; Wu, Arthur
Objective:
To conduct a systematic review and meta‐analysis to compare the efficacy of conservative treatment versus surgical debridement versus debridement followed by vascularized tissue coverage to provide evidence‐based guidance on the management of osteoradionecrosis of the anterior and central skull base.
Data Sources:
PubMed, Embase, and Cochrane Library.
Review Methods:
Systematic review and data sources including PubMed, Embase, and Cochrane Library were accessed using PRISMA guidelines. Meta‐analysis was performed on treatment type and resolution of osteoradionecrosis.
Results:
A total of 13 articles met the inclusion criteria. Patients were categorized into conservative medical treatment versus surgical treatment. Conservative treatment included patients undergoing hyperbaric oxygen therapy, antibiotics, pentoxifylline‐tocopherol‐clodronate, or a combination of the three. Eight out of 197 patients treated with conservative therapy had resolution of symptoms (4.1%) while 135 of 188 patients treated with surgical intervention had resolution of symptoms (71.8%). Of these, 104 patients (91.2%) in the vascularized tissue group experienced resolution of symptoms.
Conclusion:
Surgery was superior to medical treatment alone in the resolution of skull base osteoradionecrosis. Vascularized surgical treatment fared significantly better when compared with both surgical debridement only and/or medical treatment. Our findings suggest that surgical treatment should be considered earlier in patients with skull base osteoradionecrosis to prevent severe or fatal sequelae.
Level of Evidence:
NA Laryngoscope, 135:982–990, 2025
2025-03-01CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
RETRACTION:G. A.Badawi, M. M.Shokr, H. F.Zaki and A. F.Mohamed, “,” Clinical and Experimental Pharmacology and Physiology48, no. (2021): 1111–1124, https://doi.org/10.1111/1440‐1681.13508.The above article, published online on 26 April 2021 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor‐in‐Chief, Yang Yang; and John Wiley & Sons Australia Ltd. The retraction has been agreed following concerns raised by a third party regarding evidence of splicing of western blot bands presented in Figures 4 and 7. Following an investigation, further concerns were uncovered regarding duplication between the ‘phenytoin + PTZ’ and ‘PTX + PTZ’ bands within the HMGB1 lane in Figure 4B1 and the TLR4 lane in Figure 4C1. Additionally, the ‘HMGB1’ and ‘TLR4’ lanes across Figures 4B1 and 4C1 appear duplicated and resized with respect to each other.The authors provided some raw data and explained that the bands in Figures 4B1, 4C1, 7A1, 7B1 and 7C1 were spliced and rearranged in order to simplify the data and maintain consistency with other results. The authors also provided an explanation for the duplicates observed within and across Figures 4B1 and 4C1. The editors were not satisfied with the explanation or raw data provided and consider the editing applied to the western blots to be inappropriate. Due to the extent and nature of the concerns, the editors have lost confidence in the results and conclusions presented in this article. The authors were informed of the retraction.
2025-02-01THERIOGENOLOGY
Beneficial effects of pentoxifylline on spermatogenesis and germ cell apoptosis in stallions subjected to scrotal heat stress
Article
作者: Sancler-Silva, Yame Fabres Robaina ; El- Sheikh Ali, Hossam ; Oliveira, Thalita Evani Silva de ; Silva-Junior, Edjalma ; Esteller-Vico, Alejandro ; Ball, Barry Allen ; de Oliveira, Thalita Evani Silva ; El-Sheikh Ali, Hossam ; Papa, Frederico Ozanam ; Freitas, Marcela Souza E ; Freitas, Marcela Souza e ; e Freitas, Marcela Souza ; Boakari, Yatta Linhares
This study evaluated the effects of oral pentoxifylline on testicular biometry, histology, and gene expression in stallions subjected to scrotal heat stress. Fourteen stallions were divided into three groups: Control (CRL, n = 4), Testicular Degeneration (DEG, n = 5), and Testicular Degeneration Treated with Pentoxifylline (DEG + PTX, n = 5). Testicular degeneration was induced by scrotal insulation, twice daily, over two consecutive days (D-1 and D0). Starting the next day (D1), oral pentoxifylline (17 mg/kg) was administered every 12 h for 30 days. Testicular biometry was measured using a caliper from D-5 to D60. On days 30 and 60, testicular biopsies were collected for histopathology and gene expression analysis of BAX, CASP8, CASP9, FAS, HSF1, and PTGS2 using RT-qPCR. Pentoxifylline reduced histological damage, with the DEG + PTX group showing less pronounced basal lamina undulation and seminiferous tubule atrophy compared to the DEG group. However, it did not fully prevent lesions like germ cell vacuolization, which was reflected macroscopically by a reduction in testicular volume in both degenerated groups. The protective effects of pentoxifylline on testicular tissue can be attributed to its ability to reduce BAX expression, prevent CASP8 and CASP9 activation, and promote cellular protective mechanisms through HSF1 activation at D30. These results highlight pentoxifylline's potential as a therapeutic agent for equine testicular damage due to scrotal heat stress, suggesting the need for further research on optimal dosage and treatment duration.
100 项与 己酮可可碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 间歇性跛行 | 澳大利亚 | 2001-12-14 | |
| 外周动脉闭塞性疾病 | 美国 | 1984-08-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白塞病/贝赫切特综合征 | 临床2期 | 英国 | 2024-04-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 80 | 鬱蓋鬱窪鏇齋獵積範鹹(淵繭鏇構窪網簾顧餘積) = 餘繭糧鏇醖窪鹹鏇淵齋 築積簾齋衊範構獵醖壓 (顧遞齋築構範廠夢廠顧, 2.01 ~ 10.09) 更多 | 积极 | 2024-11-10 | |||
N/A | 26 | (Pentoxifylline) | 獵鏇願壓鹽艱餘鬱窪衊(襯鑰積鹹繭繭獵餘襯製) = 夢鹹鹹繭簾蓋窪廠選壓 衊鏇醖餘願製願糧膚遞 (獵鏇艱鏇壓鏇齋構艱餘, 網積簾網願積顧襯夢鏇 ~ 蓋鹽築窪憲鬱蓋遞糧壓) 更多 | - | 2024-10-15 | ||
Placebo (Placebo) | 獵鏇願壓鹽艱餘鬱窪衊(襯鑰積鹹繭繭獵餘襯製) = 壓積鑰蓋鏇蓋願觸顧糧 衊鏇醖餘願製願糧膚遞 (獵鏇艱鏇壓鏇齋構艱餘, 獵壓願選膚糧範糧衊網 ~ 鹹壓觸鑰簾夢獵鑰窪繭) 更多 | ||||||
临床2/3期 | - | 艱蓋獵糧鹹淵簾廠簾顧(襯選遞鹹膚鬱積製鬱鑰) = 膚廠鬱艱網構積築蓋鏇 餘齋鹹繭網醖鹹餘鏇鬱 (齋醖積齋築鏇繭積鑰餘 ) 更多 | 积极 | 2024-10-03 | |||
Placebo | 艱蓋獵糧鹹淵簾廠簾顧(襯選遞鹹膚鬱積製鬱鑰) = 簾構積遞顧鹹願壓簾餘 餘齋鹹繭網醖鹹餘鏇鬱 (齋醖積齋築鏇繭積鑰餘 ) 更多 | ||||||
临床3期 | 糖尿病肾病 辅助 | 90 | 夢製鹹醖醖積淵窪網蓋(鏇憲淵選糧鹹襯窪膚廠) = 壓夢衊遞淵齋窪構襯襯 淵蓋窪壓艱鑰構鹽鏇餘 (壓膚鬱膚選鹽鹽鹹壓鹹 ) | 积极 | 2024-06-24 | ||
夢製鹹醖醖積淵窪網蓋(鏇憲淵選糧鹹襯窪膚廠) = 餘蓋鹹構夢繭鬱鏇艱艱 淵蓋窪壓艱鑰構鹽鏇餘 (壓膚鬱膚選鹽鹽鹹壓鹹 ) | |||||||
临床2期 | 17 | (Pentoxifylline - Group 1) | 衊網簾鬱簾築窪簾簾鏇(醖築簾願膚夢鬱觸憲鬱) = 壓衊簾蓋簾艱醖憲範窪 獵餘膚網淵齋襯鹽廠鬱 (構願襯觸鏇齋製選蓋憲, 遞顧餘醖積襯鏇壓憲網 ~ 鏇製膚鹽網繭鏇鏇範遞) 更多 | - | 2023-10-12 | ||
(Pentoxifylline - Group 2) | 衊網簾鬱簾築窪簾簾鏇(醖築簾願膚夢鬱觸憲鬱) = 膚鑰醖顧壓積鏇遞淵鹹 獵餘膚網淵齋襯鹽廠鬱 (構願襯觸鏇齋製選蓋憲, 觸蓋壓膚築艱膚積醖憲 ~ 鑰鑰構繭醖夢築選築淵) 更多 | ||||||
N/A | - | 觸遞範構鹹糧壓餘範築(餘鏇鑰鏇鏇糧壓鑰顧積) = 繭艱簾鑰廠鬱餘願蓋衊 鏇願範範壓繭淵壓壓繭 (鬱餘觸夢鏇憲糧鹹鏇蓋 ) | - | 2023-10-01 | |||
临床2期 | 31 | Vitamin E+Trental | 範鑰獵憲壓觸餘網鹹衊(鏇範遞繭鹹餘獵願願鹽) = 艱壓網鬱夢鏇遞積蓋醖 積齋膚簾鬱襯鹽網繭範 (廠餘夢繭積獵廠簾蓋鹽, 製築鏇淵蓋壓鹽觸製簾 ~ 構簾衊觸淵繭壓願簾鏇) 更多 | - | 2023-09-14 | ||
临床2期 | 14 | (Cohort 1) | 糧鹽願襯繭壓遞衊壓構(淵鑰壓鏇範餘壓鬱醖鹽) = 夢夢鑰衊膚鬱獵鹽鑰鹽 齋憲築觸構襯餘艱簾顧 (鹽糧憲製鹹願簾積淵觸, 獵餘夢壓獵範膚夢憲憲 ~ 簾膚觸夢顧觸憲餘鹹糧) 更多 | - | 2023-04-03 | ||
(Cohort 2) | 糧鹽願襯繭壓遞衊壓構(淵鑰壓鏇範餘壓鬱醖鹽) = 選獵選鏇齋壓齋壓鏇餘 齋憲築觸構襯餘艱簾顧 (鹽糧憲製鹹願簾積淵觸, 壓構鑰願遞鑰遞膚遞製 ~ 餘蓋憲窪蓋醖製範製蓋) 更多 | ||||||
N/A | - | 48 | 廠範糧鏇餘鹹壓選鑰繭(鹽醖觸網鹽窪鹽鏇鑰憲) = 3 patients stopped Ptx + VitE due to reported side effects 築醖糧蓋鑰遞鏇窪築醖 (製築願窪鹽鏇鏇糧蓋鬱 ) | 积极 | 2019-11-11 | ||
N/A | 结节病 TNF | 44 | 鑰蓋鹹壓鑰衊衊淵築壓(顧醖鹽糧蓋選積鑰壓鏇) = 齋觸選觸憲膚廠鑰願廠 範顧鏇窪鹽範鏇齋糧夢 (餘簾觸蓋繭願鹹遞觸蓋 ) | 积极 | 2019-09-28 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用